February 4, 2014
Bookmark and Share  
 
                 
  HCV
»
»
»
»
»



Follow us on
Twitter

HCVAdvocate


Join us on Facebook
Hcvadvocate Hcsp

 

Alan Franciscus

 

Greetings:

In this week's E-blast we are featuring the latest and greatest news about hepatitis C and hepatitis B. I hope that everyone is surviving the strange winter, but we are coming close to Spring so hang in there!


In good health,

Alan for the awesome staff of HCV Advocate

---------------------------------------------------------------------------

Do you want to stay up to date on the latest news about hepatitis C? Visit our HCV Advocate Blog for information about hepatitis C from around the world. The pipeline is also included in our blog that provides up-to-date information about the latest clinical trials and links to more information about specific trials.

---------------------------------------------------------------------------

1. HCV Advocate Newsletter: February 2014

In This Issue:

  • HCV Drug Development News
    Alan Franciscus, Editor-in-Chief
    This month's column features the latest information about drugs in development to treat hepatitis C, including impressive results from two articles from the New England Journal of Medicine—AbbVie's interferon-free study and the controversial Gilead and BMS study. Included are pieces about the latest combination trials, and a very interesting drug that may be a one-shot cure—although it is just entering into studies with humans.

  • HEALTHWISE: Acetaminophen: Safe or Harmful?
    Lucinda K. Porter, RN

    There are two sides to every drug and this applies to acetaminophen, in many ways a wonder drug!

  • HCV and Hispanics – Prevalence
    Alan Franciscus, Editor-in-Chief
    Finally a study that breaks down the prevalence of HCV in the United States by country of origin instead of lumping everyone under one label—Hispanics.

  • DISABILITY & BENEFITS: Presumptive SSI
    Jacques Chambers, CLU

    When it comes to disability it is very important to know exactly where you stand especially prior to applying for disability benefits. Jacques outlines the information about presumptive disability programs.

  • Snapshots
    Lucinda K. Porter, RN
    Iin this month's column, Lucinda reviews studies on the prevalence of HCV, a study on the impact of treatment with sofosbuvir/ribavirin on quality of life, as well as an eye-opening study on the manufacturing costs of sofosbuvir, simeprevir, daclatasvir and faldaprevir.

 

2. HBV Journal Review by Christine Kukka —In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B, including:

  • Tests for Antigens and Drug-Resistant Virus Emerge as Valuable Diagnostic Tools
  • Experts Issue a Report Card on Side Effects from Antivirals
  • Experts Weigh in on Why They Prefer Either Antivirals or Interferon
  • Doctors Explain Which Medical Guidelines They Follow, Or Ignore
  • Truvada Effective in Lowering Viral Load in Young Adults with High Viral Load
  • Hepatitis B Causes Most Liver Cancer Deaths in China
  • Smoking Shortens Survival after Liver Cancer Surgery

-----------------------------------

 

3.Need Help?!
Call 877-HELP-4-HEP line (877-435-7443). The helpline is open from 9:00am to 7:00pm Eastern Time.

———————————————


 

 and much, much more…..

 

Sincerely,

Alan

Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

 
  HBV
»
»
»

Follow us on Twitter
HBVAdvocate